A new immunotherapy candidate has demonstrated a trend for slowing cognitive decline in mild Alzheimer’s disease (AD), potentially offering a more accessible and cost-effective alternative to other immunotherapies. Vaxxinity published the Phase IIa clinical trial data in The Lancet’s eBioMedicine (Volume 94, 104665, August 2023), stating that UB-311 was safe and well-tolerated. UB-311 is a […]